CTRI/2015/12/006434招募中4 期
Randomised open label phase IV study for patients with newly diagnosed Acute Lymphoblastic Leukaemia (Indian Childhood Collaborative Leukaemia Group Study ALL 2014) - ICiCLe ALL-14
Tata Medical Center Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Previously untreated newly-diagnosed ALL including T lymphoblastic lymphoma
排除标准
- •Previously treated patients, patients with Down syndrome and patients with mature B-A
研究者
相似试验
已完成
4 期
RituxiMab in INDuction therapy for living donor renal transplantatioive donor renal transplantationSurgeryISRCTN95769119Guy's and St Thomas' Hospital NHS Foundation Trust (UK)316
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000512-18-Outside-EU/EEAGenzyme Corporation Inc114
进行中（未招募）
1 期
A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalatioMedDRA version: 19.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2016-000191-21-CZAbbVie Deutschland GmbH & Co. KG240
进行中（未招募）
1 期
A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalatioMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2016-000191-21-ITABBVIE DEUTSCHLAND GMBH & CO. KG245
进行中（未招募）
1 期
A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalatioPsoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2016-000191-21-DEAbbVie Deutschland GmbH & Co. KG240